Dr. Roger Hajjar is the Director of the Gene and Cell Therapy Institute at Mass General Brigham in Boston, Massachusetts. He has been at the forefront of the development and translation of cardiac gene therapy from early-stage research through to clinical trials. Under his leadership, his laboratory has identified and validated multiple cardiac therapeutic targets, which have culminated in the successful initiation and completion of First-in-Human gene therapy clinical trials for patients suffering from various forms of heart failure and cardiomyopathies. Dr. Hajjar is the co- founder of several gene therapy enterprises, including Nanocor/AskBio and Medera, which are actively advancing therapeutic programs targeting both rare and prevalent forms of cardiomyopathy.
